Author: Yash Jani, Medical College of Georgia, Augusta, USA
Citation: Dermatol AMJ. 2026;3[1]:34-37. https://doi.org/10.33590/dermatolamj/A01I6L47
RECENT updates to the American Academy of Dermatology (AAD) guidelines have marked a pivotal shift in the management of pediatric atopic dermatitis, reflecting the rapid evolution of targeted immunomodulatory therapies and a growing emphasis on long-term disease control. This congress feature highlights key discussions surrounding the transition away from systemic corticosteroids, the expanding role of biologics and JAK inhibitors, and the broader implications of these changes for clinical practice. In addition, it explores ongoing challenges related to access, safety, and health equity, underscoring the need to translate therapeutic innovation into meaningful improvements in outcomes for pediatric patients.
INTRODUCTION
After more than a decade of relative therapeutic stagnation, the AAD has released updated guidelines for the management of pediatric atopic dermatitis, marking a pivotal inflection point in the field.¹ These recommendations arrive at a time when the therapeutic landscape has been fundamentally reshaped by the rapid expansion of targeted immunomodulatory therapies, including biologics and JAK inhibitors. Together, these advances have transformed what was once a disease managed largely with topical agents and systemic corticosteroids into one that can now be treated with precision-based, mechanism-driven interventions.
Perhaps the most striking aspect of the updated guidelines is the strong recommendation against systemic corticosteroids.1,2 This shift reflects not only a growing body of evidence highlighting the risks associated with corticosteroid use in children, but also the availability of safer and more effective alternatives. In this context, the 2026 guidelines do not merely update prior recommendations, they redefine the standard of care.
THE THERAPEUTIC REVOLUTION
The scope of therapeutic advancement in atopic dermatitis over the past decade is unprecedented. Dupilumab, the first biologic approved for atopic dermatitis, is now indicated for children as young as 6 months.1,3 Clinical trials in infants and young children have demonstrated robust efficacy, with significantly higher rates of skin clearance and rapid improvement in disease severity compared to placebo.³ Notably, treatment responses are observed within weeks, and safety profiles appear consistent across pediatric and adult populations.³
Beyond dupilumab, the biologic landscape has expanded to include agents targeting IL-13 (tralokinumab, lebrikizumab) and IL-31 (nemolizumab) pathways, further refining the ability to modulate Type 2 inflammation.4 These therapies offer the potential for sustained disease control with fewer systemic adverse effects compared to traditional immunosuppressive agents. In parallel, JAK inhibitors, including upadacitinib, abrocitinib, and baricitinib, have emerged as powerful oral alternatives that act downstream of multiple cytokine signaling pathways.3,4 Network meta-analyses suggest that certain JAK inhibitors may achieve higher rates of near-complete skin clearance and more rapid itch reduction compared to biologics, although these benefits must be weighed against evolving safety considerations.3,5
Importantly, real-world data increasingly support the durability of targeted therapies. Dupilumab demonstrates superior long-term drug survival compared to conventional systemic agents such as methotrexate and cyclosporine, with lower discontinuation rates due to treatment failure.3 These findings underscore a paradigm shift from episodic symptom suppression to sustained disease modification.
THE CASE AGAINST SYSTEMIC CORTICOSTEROIDS
The strong recommendation against systemic corticosteroids represents a long-overdue reassessment of their role in pediatric atopic dermatitis.1,2 Although corticosteroids provide rapid symptomatic relief, their effects are often transient, with disease recurrence frequently occurring upon discontinuation.6-8
More concerning, however, are the well-documented risks associated with systemic corticosteroid use, even when administered for short durations. These include increased risks of infection, venous thromboembolism, and fracture.2,9,10 In pediatric populations, additional concerns include growth suppression, adrenal insufficiency, metabolic disturbances, and neuropsychiatric effects.11
In clinical practice, corticosteroids are often used in repeated short courses, creating a cycle of temporary improvement followed by rebound flares.2 This pattern not only exposes children to cumulative toxicity, but also delays the initiation of more appropriate long-term therapies. As newer, targeted agents become increasingly accessible, the continued reliance on systemic corticosteroids appears increasingly difficult to justify.
REDEFINING TREATMENT GOALS
The emergence of targeted therapies has fundamentally altered treatment goals in pediatric atopic dermatitis. Historically, management focused on reducing acute inflammation and alleviating symptoms. Today, the emphasis has shifted toward achieving sustained disease control, improving quality of life, and minimizing long-term morbidity.
Biologic therapies have demonstrated meaningful improvements not only in clinical severity, but also in patient-reported outcomes, including sleep quality, psychosocial functioning, and caregiver burden.12 These benefits are particularly important in pediatric populations, where chronic skin disease can have profound effects on development, self-esteem, and social integration.
At the same time, advances in non-steroidal topical therapies, including phosphodiesterase-4 inhibitors (crisaborole, roflumilast), topical JAK inhibitors (ruxolitinib), and aryl hydrocarbon receptor modulators (tapinarof), have expanded treatment options for patients with milder disease.13,14 This growing therapeutic armamentarium allows for more individualized, stepwise approaches to care.
However, treatment selection remains complex. While JAK inhibitors may offer rapid onset of action and high levels of efficacy, biologics such as dupilumab provide a longer safety track record and broader applicability across age groups.15 The decision between these options must be guided by patient-specific factors, including age, comorbid conditions, route of administration preferences, and risk tolerance.
IMPLEMENTATION CHALLENGES AND HEALTH EQUITY
Despite these advances, significant barriers to implementation persist. Cost and insurance coverage remain major obstacles to accessing biologic therapies, particularly for younger children.² Prior authorization requirements, variable payer policies, and high out-of-pocket costs can delay or prevent initiation of appropriate treatment.
Disparities in access are further compounded by gaps in clinical trial data for the youngest patients. Although dupilumab is approved for infants as young as 6 months, many newer agents remain restricted to older pediatric populations, leading to reliance on off-label use in younger age groups.13,15
These challenges highlight a critical need for coordinated efforts to improve access to care. Dermatologists, pediatricians, and healthcare systems must work collaboratively to ensure that advances in therapy translate into real-world improvements in patient outcomes.
LOOKING FORWARD
The 2026 AAD guidelines represent more than an update: they signal a fundamental shift in how pediatric atopic dermatitis is conceptualized and managed. The move away from systemic corticosteroids toward targeted, mechanism-based therapies reflects a maturation of the evidence base and a redefinition of therapeutic priorities.
However, important questions remain. Long-term safety data for newer agents, particularly in very young children, are still evolving. Additionally, the optimal sequencing of therapies and strategiesfor treatment de-escalation have yet to be fully defined.
Perhaps most importantly, the field must address persistent disparities in access to care. The benefits of therapeutic innovation can only be realized if they are available to all patients, regardless of socioeconomic status or geographic location.
CONCLUSION
Pediatric atopic dermatitis is no longer a condition defined by therapeutic limitation. The emergence of biologics and JAK inhibitors has ushered in a new era of precision medicine, enabling clinicians to move beyond symptom control toward sustained disease modification.
In this context, the strong recommendation against systemic corticosteroids is both timely and necessary. It reflects not only a growing recognition of their risks, but also the availability of superior alternatives. As the field continues to evolve, the focus must shift from expanding therapeutic options to ensuring their appropriate and equitable use. Only then can the full potential of these advances be realized for the millions of children affected by atopic dermatitis worldwide.
